Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol.

Chen X, Chen SL, He YX, Ye DS.

J Huazhong Univ Sci Technolog Med Sci. 2013 Feb;33(1):133-6. doi: 10.1007/s11596-013-1085-z. Epub 2013 Feb 8.

PMID:
23392722
3.

GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.

Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY.

Hum Reprod. 2013 Sep;28(9):2511-21. doi: 10.1093/humrep/det249. Epub 2013 Jun 9.

PMID:
23753114
4.

GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

O'Neill KE, Senapati S, Maina I, Gracia C, Dokras A.

J Assist Reprod Genet. 2016 Sep;33(9):1175-84. doi: 10.1007/s10815-016-0755-8. Epub 2016 Jun 27.

5.

New algorithm for OHSS prevention.

Papanikolaou EG, Humaidan P, Polyzos N, Kalantaridou S, Kol S, Benadiva C, Tournaye H, Tarlatzis B.

Reprod Biol Endocrinol. 2011 Nov 3;9:147. doi: 10.1186/1477-7827-9-147.

6.
7.

Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.

Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L.

Fertil Steril. 2012 Jun;97(6):1316-20. doi: 10.1016/j.fertnstert.2012.03.015. Epub 2012 Apr 3.

PMID:
22480822
8.

Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.

Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH.

Hum Reprod. 2013 Sep;28(9):2522-8. doi: 10.1093/humrep/det124. Epub 2013 Apr 30.

PMID:
23633553
9.

The prevention of ovarian hyperstimulation syndrome.

Corbett S, Shmorgun D, Claman P; REPRODUCTIVE ENDOCRINOLOGY INFERTILITY COMMITTEE; SPECIAL CONTRIBUTOR.

J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. Review. English, French.

PMID:
25574681
10.

Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.

Christopoulos G, Vlismas A, Barsoum-Derias E, El-Shawarby S, Trew G, Lavery S.

Hum Fertil (Camb). 2015;18(4):248-52. doi: 10.3109/14647273.2015.1071500. Epub 2015 Sep 23.

PMID:
26400626
11.

Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.

Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS.

Fertil Steril. 2008 Dec;90(6):2172-8. doi: 10.1016/j.fertnstert.2007.10.033. Epub 2008 Apr 25.

PMID:
18439601
12.

Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.

Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R.

Reprod Biomed Online. 2006 Aug;13(2):198-201.

PMID:
16895632
13.

Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.

Tannus S, Turki R, Cohen Y, Son WY, Shavit T, Dahan MH.

Fertil Steril. 2017 Jun;107(6):1323-1328.e2. doi: 10.1016/j.fertnstert.2017.04.014. Epub 2017 May 10.

PMID:
28501366
14.

Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.

Griesinger G, Verweij PJ, Gates D, Devroey P, Gordon K, Stegmann BJ, Tarlatzis BC.

PLoS One. 2016 Mar 7;11(3):e0149615. doi: 10.1371/journal.pone.0149615. eCollection 2016.

15.

Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.

Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, Nelson SM.

Hum Reprod. 2013 Sep;28(9):2529-36. doi: 10.1093/humrep/det304. Epub 2013 Jul 19.

PMID:
23873146
16.

GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.

Christopoulos G, Vlismas A, Carby A, Lavery S, Trew G.

Hum Fertil (Camb). 2016 Sep;19(3):199-206. doi: 10.1080/14647273.2016.1217432. Epub 2016 Aug 9.

PMID:
27662416
17.

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.

Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008046. doi: 10.1002/14651858.CD008046.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD008046.

PMID:
21069701
18.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.

Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O.

Fertil Steril. 2009 Feb;91(2):365-71. doi: 10.1016/j.fertnstert.2007.11.049. Epub 2008 Mar 25.

PMID:
18367175
19.

GnRHa to trigger final oocyte maturation: a time to reconsider.

Humaidan P, Papanikolaou EG, Tarlatzis BC.

Hum Reprod. 2009 Oct;24(10):2389-94. doi: 10.1093/humrep/dep246. Epub 2009 Jul 16. Review.

PMID:
19608565
20.

Supplemental Content

Support Center